Stay updated on Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page
- Check5 days agoChange DetectedThe Study Details page for NCT05155085 appears unchanged between the two screenshots, with no visible edits to study design, eligibility criteria, outcomes, or site list.SummaryDifference0.3%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%

- Check34 days agoChange DetectedThe page now shows Revision: v3.1.0 and removes several drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the content, indicating a restructuring and possible narrowing of the domain coverage.SummaryDifference0.4%

- Check48 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2 and the Back to Top link was removed; no substantive changes to core content.SummaryDifference0.2%

- Check55 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.2%

- Check62 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and specific drug safety information, while removing previous location details and versioning information.SummaryDifference2%

Stay in the know with updates to Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.